Vivo Surgical Announces Acceptance into Mount Sinai Innovation Partners Strategic Virtual Incubator

Updated: May 23


Vivo Surgical announces acceptance into Mount Sinai Innovation Partners Strategic Virtual Incubator, Elementa Labs


Press Release, 19 May 2022


Vivo Surgical, a pioneering medical device company based in Singapore, has been selected to join the prestigious Elementa Labs program run by Mount Sinai Innovation Partners (MSIP), the commercialization arm of the Mount Sinai Health System (Mount Sinai) in New York, NY. Vivo Surgical is joining the program’s 2022 cohort and is the first Asian company in their portfolio. Elementa Labs is a strategic virtual incubator that positions healthcare and biotechnology start-ups for the next stage in their development. The company will be exploring ways to optimize, expand, and advance their core technology platforms for the North American market with the Mount Sinai Health System.


Dr Kevin Koh, CEO of Vivo Surgical, said: “Vivo Surgical is pleased to embark on this new relationship with Mount Sinai, which dovetails with our growth strategy in the USA. Our teams look forward to working with clinicians and experts from Mount Sinai to understand the adoption and growth of our product portfolio, starting with KLARO™ and ENLYT™, in North America and beyond.”


For further information on Vivo Surgical visit www.vivo-surgical.com.


About Vivo Surgical

Vivo Surgical is a clinically-driven, patient-centric innovator and manufacturer in surgical technology and robotics. Headquartered in Singapore, its unique products target the medical needs of the world through innovative applications of science & technology. ISO 13485 certified with international accreditations awarded such as the US FDA, European CE mark and Singaporean HSA, the company's proprietary technologies encompass fields such as deep-cavity in vivo surgical LED lighting, flexible nasopharyngoscopy and minimally-invasive robotic surgery.